Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;29(4):1941-1950.
doi: 10.1007/s00520-020-05684-7. Epub 2020 Aug 18.

Oncology patients' perceptions of and experiences with COVID-19

Christine Miaskowski  1   2 , Steven M Paul  3 , Karin Snowberg  3 , Maura Abbott  4 , Hala Borno  5 , Susan Chang  5 , Lee May Chen  5 , Bevin Cohen  6 , Bruce A Cooper  3 , Marilyn J Hammer  7 , Stacey A Kenfield  5 , Angela Laffan  5 , Jon D Levine  5 , Rachel Pozzar  7 , Katy K Tsai  5 , Erin L Van Blarigan  5 , Katherine Van Loon  5
Affiliations

Oncology patients' perceptions of and experiences with COVID-19

Christine Miaskowski et al. Support Care Cancer. 2021 Apr.

Abstract

Purpose: No information is available on cancer patients' knowledge of and experiences with COVID-19. We undertook an evaluation of differences in COVID-19 symptom occurrence rates, COVID-19 testing rates, clinical care activities, knowledge of COVID-19, and use of mitigation procedures between patients who were and were not receiving active cancer treatment.

Methods: Patients enrolled were > 18 years of age; had a diagnosis of cancer; and were able to complete the emailed study survey online.

Results: Of the 174 patients who participated, 27.6% (n = 48) were receiving active treatment, 13.6% were unemployed because of COVID-19, 12.2% had been tested for COVID-19, and 0.6% had been hospitalized for COVID-19. Patients who were not on active treatment reported a higher mean number of COVID-19 symptoms (3.1 (± 4.2) versus 1.9 (± 2.6)), and patients who reported a higher number of COVID-19 symptoms were more likely to be tested. Over 55% of the patients were confident that their primary care provider could diagnose COVID-19, and the majority of the patients had high levels of adherence with the use of precautionary measures (e.g., social distancing, use of face coverings).

Conclusion: The high level of COVID-19 symptoms and the significant overlap of COVID-19 and cancer-related symptoms pose challenges for clinicians who are assessing and triaging oncology patients for COVID-19 testing. For patients on active treatment, clinicians face challenges with how to assess and manage symptoms that, prior to COVID-19, would be ascribed to acute toxicities associated with cancer treatments or persistent symptoms in cancer survivors.

Keywords: COVID-19; Cancer; Fears; Mitigation procedures; Perceptions; Symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/s0140-6736(20)30211-7. - DOI - PMC - PubMed
    1. Robinson AG, Gyawali B, Evans G. COVID-19 and cancer: do we really know what we think we know? Nat Rev Clin Oncol. 2020;17(7):386–388. doi: 10.1038/s41571-020-0394-y. - DOI - PMC - PubMed
    1. Robinson A, Gyawali B, Booth CM (2020a) Risk of COVID-19 in patients with cancer. JAMA Oncol. 10.1001/jamaoncol.2020.2586 - PubMed
    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi: 10.1016/s1470-2045(20)30096-6. - DOI - PMC - PubMed
    1. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Covid CC. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed

MeSH terms